Pidotimod

Pidotimod is an immunostimulant.(In Vivo):In toxicology study in animals, Pidotimod (oral gavage; 800 mg/kg;12 months) is non-toxic in rats and is non-toxic dogs at 600 mg/kg. Pidotimod is non-teratogenic in rats (600 mg/kg orally or 1000 mg/kg IV) and has no effects on subsequent embryofoetal development in rats (up to 1000 mg/kg/day),it has no perinatal or postnatal toxic effects in rats (600 mg/kg orally).In ex vivo experiments in mice, Pidotimod (intraperitoneal administration; 200 mg/kg; 5 days) potentiats natural killer (NK) cell activity and produces an increase in the proliferative response to mitogens such as concanavalin A (ConA) and interleukin-2 (IL-2).Pidotimod (intraperitoneal administration; 10-100 mg/kg) normalizes depletion of peritoneal macrophage numbers, and significantly increases macrophage superoxide anion (O2–) production in methylprednisolone-induced immunosuppressed mice.